相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clash of the Cytokine Titans: counter-regulation of interleukin-1 and type I interferon-mediated inflammatory responses
Katrin D. Mayer-Barber et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2017)
Rethinking the INN system for therapeutic antibodies
Jeremy Pottier et al.
MABS (2017)
Advanced colorectal cancer treatment options beyond standard systemic therapy
Timothy J. Price
LANCET ONCOLOGY (2017)
MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study
Tamas Hickish et al.
LANCET ONCOLOGY (2017)
Proceedings of the third international molecular pathological epidemiology (MPE) meeting
Peter T. Campbell et al.
CANCER CAUSES & CONTROL (2017)
Interleukins 1 and 6 as main mediators of inflammation and cancer
O. S. Dmitrieva et al.
BIOCHEMISTRY-MOSCOW (2016)
Novel therapeutic options for cachexia and sarcopenia
Alessio Molfino et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
Phase III double-blinded, placebo-controlled study of MABp1 for improving survival in metastatic colorectal cancer.
Sanjay Goel et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A randomized phase II study of Xilonix, a targeted therapy against interleukin 1 alpha, for the prevention of superficial femoral artery restenosis after percutaneous revascularization
Hosam El Sayed et al.
JOURNAL OF VASCULAR SURGERY (2016)
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
Randy F. Sweis et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer
David S. Hong et al.
INVESTIGATIONAL NEW DRUGS (2015)
Safety, pharmacokinetics, and preliminary efficacy of a specific anti-IL-1alpha therapeutic antibody (MABp1) in patients with type 2 diabetes mellitus
Katharina Timper et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2015)
Prognostic nomogram integrated systemic inflammation score for patients with esophageal squamouscell carcinoma undergoing radical esophagectomy
Yingjie Shao et al.
SCIENTIFIC REPORTS (2015)
Reporting of MABp1 for the Treatment of Psoriasis
Bobbak Mansouri et al.
JAMA DERMATOLOGY (2015)
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
Nicolas J. Llosa et al.
CANCER DISCOVERY (2015)
Interleukin-1α neutralisation in patients with cancer
Charles Anthony Dinarello
LANCET ONCOLOGY (2014)
MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study
David S. Hong et al.
LANCET ONCOLOGY (2014)
Trends in Overall and Cause-Specific Mortality Among Patients With Inflammatory Bowel Disease From 1982 to 2010
Tine Jess et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Prognostic Nomogram for Intrahepatic Cholangiocarcinoma After Partial Hepatectomy
Yizhou Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The value of progression-free survival to patients with advanced-stage cancer
Lesley J. Fallowfield et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Charles A. Dinarello et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Cancer-related inflammation: Common themes and therapeutic opportunities
Frances R. Balkwill et al.
SEMINARS IN CANCER BIOLOGY (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Alternative End Points to Evaluate a Therapeutic Strategy in Advanced Colorectal Cancer: Evaluation of Progression-Free Survival, Duration of Disease Control, and Time to Failure of Strategy-An Aide et Recherche en Cancerologie Digestive Group Study
Benoist Chibaudel et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial
John Burn et al.
LANCET (2011)
Comparison of the Prognostic Value of Tumour- and Patient-Related Factors in Patients Undergoing Potentially Curative Resection of Oesophageal Cancer
Sumanta Dutta et al.
WORLD JOURNAL OF SURGERY (2011)
Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component
John A. Lust et al.
MAYO CLINIC PROCEEDINGS (2009)
IL-1, IL-18, and IL-33 families of cytokines
William P. Arend et al.
IMMUNOLOGICAL REVIEWS (2008)
Pathophysiology of Cancer-Related Fatigue
Xin Shelley Wang
CLINICAL JOURNAL OF ONCOLOGY NURSING (2008)
Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab
S. Siena et al.
BRITISH JOURNAL OF CANCER (2007)
Progression-free survival is a surrogate for survival in advanced colorectal cancer
Marc Buyse et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Health-related quality of life and symptom management research sponsored by the National Cancer Institute
Lori M. Minasian et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions
Ron N. Apte et al.
CANCER AND METASTASIS REVIEWS (2006)
IL-1 is required for tumor invasiveness and angiogenesis
E Voronov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
分享论文
